サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：肺動脈性肺高血圧症市場、シェア、規模、動向、産業分析レポート：タイプ別、薬剤クラス別、投与経路別、地域別、セグメント別予測、2023年～2032年
市場調査レポート
商品コード
1421703

肺動脈性肺高血圧症市場、シェア、規模、動向、産業分析レポート：タイプ別、薬剤クラス別、投与経路別、地域別、セグメント別予測、2023年～2032年

Pulmonary Arterial Hypertension Market Share, Size, Trends, Industry Analysis Report, By Type (Generics, Branded); By Drug Class; By Route of Administration; By Region; Segment Forecast, 2023 - 2032
出版日: | 発行: Polaris Market Research | ページ情報: 英文 115 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
肺動脈性肺高血圧症市場、シェア、規模、動向、産業分析レポート：タイプ別、薬剤クラス別、投与経路別、地域別、セグメント別予測、2023年～2032年
出版日: 2023年11月23日
発行: Polaris Market Research
ページ情報: 英文 115 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、世界の肺動脈性肺高血圧症市場規模は2032年までに113億5,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

このような健康状態に罹患しやすい高齢者人口の増加により、心血管障害や肺疾患の有病率が増加していることが、今後数年間における肺動脈性肺高血圧症（PAH）市場の拡大を牽引する見通しです。さらに、過度のアルコール摂取、座りがちな生活、不健康な食生活などの生活習慣の悪化が、高血圧や高脂血症のリスクを高めています。このことは、肺動脈性肺高血圧症（PAH）に対する新規希少薬や技術的に進歩した治療装置のインダクション、PAHに対する利用可能な治療選択肢に関する一般市民の意識の高まり、ヘルスケア・インフラの改善と相まって、肺動脈性肺高血圧症（PAH）市場のさらなる成長に拍車をかけると予想されます。しかし、厳しい薬事規制が、今後の市場成長に対する課題となっています。

PAHの症状はさまざまで、息切れ、疲労、胸痛、めまい、失神、足や脚、胃のむくみなどがあります。これらの症状は時間の経過とともに進行し、個人のQOLに大きな影響を与えます。PAHは進行性の疾患であり、右心不全、不整脈、肺血栓などの合併症を引き起こし、重症の場合は死亡することもあります。したがって、早期の診断と治療が、この疾患を効果的に管理する上で重要な役割を果たします。PAH患者には、呼吸器専門医、循環器専門医、その他の専門家からなる専門医療チームによる定期的なモニタリングが不可欠です。彼らは病状を監督し、必要な薬物調整を行い、重要なサポートを提供することができます。さらに、定期的な運動、バランスの取れた食事の維持、喫煙や呼吸器への刺激を避けるといった生活習慣の改善も、効果的な病状管理を促進するために勧められます。

さらに、2021年6月にNational Library of Medicineに掲載された研究では、冠動脈疾患（CAD）が世界の健康に与える影響の大きさが強調されています。CADだけで年間約61万人が死亡しており、推定死亡者数の4人に1人を占め、米国における死亡原因の第1位となっています。CADの発症率が上昇するにつれ、この差し迫った医療ニーズに対処するための効果的な肺動脈性肺高血圧症治療器に対する需要が高まっています。その結果、この要因が予測期間を通じて肺動脈性肺高血圧症の需要を促進すると予測されています。

肺動脈性肺高血圧症市場レポートハイライト

2022年、プロスタサイクリンおよびプロスタサイクリン類似体セグメントは、旺盛な需要と用途の拡大に起因して、市場で最大の収益シェアを主張しました。さらに、SGC刺激剤セグメントは、CAGRが5%を超え、最も急速な成長が見込まれています。SGC刺激剤は、NO-sGCシグナル伝達を増強し、sGCの活性化を最大化することが期待されています。

予測期間中、経口薬セグメントは市場を独占していたが、これは主に肺動脈性肺高血圧症に対する経口製剤の入手可能性が高まっていることと、患者が経口投与を好むためです。経口PAH治療薬の注目すべき例としては、Letairis、Adcirca、Opsumit、Revatioなどが挙げられます。

2022年には、北米が世界市場をリードしたが、これは主に米国とカナダにおける確立されたヘルスケア・インフラが、高度な治療アクセスを容易にしていることによる。さらに、認知度の向上、診断率の高さ、政府の支援策がこの地域の市場成長に寄与しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の肺動脈性肺高血圧症市場に関する洞察

  • 肺動脈性肺高血圧症市場- 投与経路のスナップショット
  • 肺動脈性肺高血圧症市場力学
    • 促進要因と機会
      • 肺動脈性肺高血圧症（PAH）の症例が市場の成長を促進
      • 可溶性グアニル酸シクラーゼ（SGC）刺激薬の進歩
    • 抑制要因と課題
      • 重要な特許の失効
  • PESTEL分析
  • 肺動脈性肺高血圧症市場の投与経路動向
  • バリューチェーン分析
  • COVID-19感染症の影響分析

第5章 世界の肺動脈性肺高血圧症市場、薬剤クラス別

  • 主な調査結果
  • イントロダクション
  • PDE-5阻害剤
  • プロスタサイクリンおよびプロスタサイクリン類似体
  • SGC刺激装置
  • エンドセリン受容体拮抗薬（ERA）

第6章 世界の肺動脈性肺高血圧症市場、タイプ別

  • 主な調査結果
  • イントロダクション
  • ジェネリック
  • ブランド

第7章 世界の肺動脈性肺高血圧症市場、投与経路別

  • 主な調査結果
  • イントロダクション
  • 静脈内/皮下
  • 吸入用
  • オーラル

第8章 世界の肺動脈性肺高血圧症市場、地域別

  • 主な調査結果
  • イントロダクション
    • 肺動脈性肺高血圧症市場評価、地域、2019-2032年
  • 肺動脈性肺高血圧症市場-北米
    • 北米：肺動脈性肺高血圧症市場、薬剤クラス別、2019-2032年
    • 北米：肺動脈性肺高血圧症市場、投与経路別、2019～2032年
    • 北米：肺動脈性肺高血圧症市場、タイプ別、2019-2032年
    • 肺動脈性肺高血圧症市場-米国
    • 肺動脈性肺高血圧症市場- カナダ
  • 肺動脈性肺高血圧症市場- 欧州
    • 欧州：肺動脈性肺高血圧症市場、薬剤クラス別、2019～2032年
    • 欧州：肺動脈性肺高血圧症市場、投与経路別、2019～2032年
    • 欧州：肺動脈性肺高血圧症市場、タイプ別、2019～2032年
    • 肺動脈性肺高血圧症市場- 英国
    • 肺動脈性肺高血圧症市場- フランス
    • 肺動脈性肺高血圧症市場- ドイツ
    • 肺動脈性肺高血圧症市場- イタリア
    • 肺動脈性肺高血圧症市場- スペイン
    • 肺動脈性肺高血圧症市場- オランダ
    • 肺動脈性肺高血圧症市場- ロシア
  • 肺動脈性肺高血圧症市場- アジア太平洋
    • アジア太平洋：肺動脈性肺高血圧症市場、薬剤クラス別、2019～2032年
    • アジア太平洋：肺動脈性肺高血圧症市場、投与経路別、2019～2032年
    • アジア太平洋：肺動脈性肺高血圧症市場、タイプ別、2019～2032年
    • 肺動脈性肺高血圧症市場- 中国
    • 肺動脈性肺高血圧症市場- インド
    • 肺動脈性肺高血圧症市場- マレーシア
    • 肺動脈性肺高血圧症市場- 日本
    • 肺動脈性肺高血圧症市場- インドネシア
    • 肺動脈性肺高血圧症市場- 韓国
  • 肺動脈性肺高血圧症市場-中東およびアフリカ
    • 中東およびアフリカ：肺動脈性肺高血圧症市場、薬剤クラス別、2019～2032年
    • 中東およびアフリカ：肺動脈性肺高血圧症市場、投与経路別、2019～2032年
    • 中東およびアフリカ：肺動脈性肺高血圧症市場、タイプ別、2019～2032年
    • 肺動脈性肺高血圧症市場- サウジアラビア
    • 肺動脈性肺高血圧症市場- アラブ首長国連邦
    • 肺動脈性肺高血圧症市場- イスラエル
    • 肺動脈性肺高血圧症市場- 南アフリカ
  • 肺動脈性肺高血圧症市場-ラテンアメリカ
    • ラテンアメリカ：肺動脈性肺高血圧症市場、薬剤クラス別、2019-2032年
    • ラテンアメリカ：肺動脈性肺高血圧症市場、投与経路別、2019-2032
    • ラテンアメリカ：肺動脈性肺高血圧症市場、タイプ別、2019-2032年
    • 肺動脈性肺高血圧症市場- メキシコ
    • 肺動脈性肺高血圧症市場- ブラジル
    • 肺動脈性肺高血圧症市場- アルゼンチン

第9章 競合情勢

  • 拡張と買収の分析
    • 拡大
    • 買収
  • 提携/協業/合意/公開

第10章 企業プロファイル

  • Bayer
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Johnson & Johnson
  • Lupin Pharmaceuticals, Inc.
  • Sandoz Inc.（Novartis）
  • Sun Pharmaceutical Industries, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • United Therapeutics Corporation
  • Viatris Inc.
図表

List of Tables

  • Table 1 Global Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 2 Global Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 3 Global Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 4 Pulmonary Arterial Hypertension Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 6 North America: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 7 North America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 8 U.S.: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 9 U.S.: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 10 U.S.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 11 Canada: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 12 Canada: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 13 Canada: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 14 Europe: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 15 Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 16 Europe: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 17 UK: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 18 UK: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 19 UK: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 20 France: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 21 France: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 22 France: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 23 Germany: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 24 Germany: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 25 Germany: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 26 Italy: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 27 Italy: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 28 Italy: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 29 Spain: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 30 Spain: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 31 Spain: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 35 Russia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 36 Russia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 37 Russia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 41 China: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 42 China: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 43 China: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 44 India: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 45 India: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 46 India: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 50 Japan: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 51 Japan: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 52 Japan: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 56 South Korea: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 57 South Korea: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 58 South Korea: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 65 UAE: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 66 UAE: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 67 UAE: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 68 Israel: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 69 Israel: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 70 Israel: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 71 South Africa: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 72 South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 73 South Africa: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 74 Latin America: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 75 Latin America: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 76 Latin America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 77 Mexico: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 78 Mexico: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 79 Mexico: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 80 Brazil: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 81 Brazil: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 82 Brazil: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • Table 83 Argentina: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 84 Argentina: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • Table 85 Argentina: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Pulmonary Arterial Hypertension Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Type
  • Figure 7. Global Pulmonary Arterial Hypertension Market, by Type, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Drug Class
  • Figure 9. Global Pulmonary Arterial Hypertension Market, by Drug Class, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Route of Administration
  • Figure 11. Global Pulmonary Arterial Hypertension Market, by Route of Administration, 2022 & 2032 (USD Billion)
  • Figure 12. Pulmonary Arterial Hypertension Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Pulmonary Arterial Hypertension Market
目次
Product Code: PM4051

The global pulmonary arterial hypertension market size is expected to reach USD 11.35 billion by 2032, according to a new study by Polaris Market Research. The report "Pulmonary Arterial Hypertension Market Share, Size, Trends, Industry Analysis Report, By Type (Generics, Branded); By Drug Class; By Route of Administration; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing prevalence of cardiovascular and pulmonary disorders, driven by a growing elderly population susceptible to such health conditions, is poised to drive the pulmonary arterial hypertension (PAH) market's expansion in the forthcoming years. Moreover, lifestyle modifications, such as excessive alcohol consumption, sedentary behavior, and unhealthy dietary habits, have heightened the risk of hypertension and high blood pressure. This, combined with the introduction of novel orphan drugs and technologically advanced treatment devices for pulmonary arterial hypertension (PAH), increased awareness among the public regarding available treatment options for PAH, and improved healthcare infrastructure, is expected to fuel further the growth of the pulmonary arterial hypertension (PAH) market. However, stringent drug regulations pose a challenge to the market's growth in the years ahead.

Symptoms of PAH can exhibit variability and may encompass shortness of breath, fatigue, chest pain, dizziness, fainting, and swelling in the feet, legs, and stomach. Over time, these symptoms can progress, significantly impacting an individual's quality of life. PAH is a progressive ailment that may lead to complications, including right-sided heart failure, arrhythmias, lung blood clots, and, in severe instances, mortality. Therefore, early diagnosis and treatment play a vital role in effectively managing the condition. Regular monitoring by a specialized healthcare team comprising pulmonologists, cardiologists, and other experts is essential for individuals with PAH. They can oversee the condition, make necessary medication adjustments, and provide vital support. Furthermore, lifestyle changes like regular exercise, maintaining a balanced diet, and avoiding smoking and respiratory irritants may be advised to facilitate effective condition management.

Additionally, a study published in the National Library of Medicine in June 2021 highlighted the significant impact of coronary artery disease (CAD) on global health. CAD alone is responsible for approximately 610,000 deaths annually, accounting for an estimated one in four deaths and making it the foremost cause of mortality in the United States. With the incidence of CAD rising, there is a growing demand for effective Pulmonary Arterial Hypertension devices to address this pressing medical need. Consequently, this factor is projected to drive the demand for Pulmonary Arterial Hypertensions throughout the forecast period.

Pulmonary Arterial Hypertension Market Report Highlights

In 2022, the Prostacyclin and Prostacyclin Analogs segment claimed the largest share of revenue in the market, attributed to robust demand and expanding applications. Additionally, the SGC stimulators segment is expected to exhibit the swiftest growth, featuring a CAGR surpassing 5%. SGC stimulators hold promise for enhancing NO-sGC signaling and maximizing sGC activation.

During the forecast period, the Oral segment dominated the market, primarily due to the growing availability of oral formulations for pulmonary arterial hypertension and patient preference for oral administration. Notable examples of oral PAH drugs comprise Letairis, Adcirca, Opsumit, and Revatio.

In 2022, North America led the global market, primarily driven by its well-established healthcare infrastructure in the United States and Canada, facilitating advanced therapeutic access. Moreover, increased awareness, a high diagnosis rate, and government support initiatives contribute to the market's growth in this region.

The global key market players include: Bayer, Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Lupin Pharmaceuticals, Inc., Sandoz Inc. (Novartis), Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., United Therapeutics Corporation, and Viatris Inc.

Polaris Market Research has segmented the Pulmonary Arterial Hypertension market report based on type, drug class, route of administration, and region:

Pulmonary Arterial Hypertension, Type Outlook (Revenue - USD Billion, 2019 - 2032)

  • Generics
  • Branded

Pulmonary Arterial Hypertension, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • PDE-5 Inhibitors
  • Prostacyclin and Prostacyclin Analogs
  • SGC Stimulators
  • Endothelin Receptor Antagonists (ERAs)

Pulmonary Arterial Hypertension, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Intravenous/ subcutaneous
  • Inhalational
  • Oral

Pulmonary Arterial Hypertension, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Pulmonary Arterial Hypertension Market Insights

  • 4.1. Pulmonary Arterial Hypertension Market - Route of Administration Snapshot
  • 4.2. Pulmonary Arterial Hypertension Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Cases of Pulmonary Arterial Hypertension (PAH) Facilitate Market Growth
      • 4.2.1.2. Advancement of soluble guanylate cyclase (SGC)-stimulating drugs
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Expiration of critical patents
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Pulmonary Arterial Hypertension Market Route of Administration Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Pulmonary Arterial Hypertension Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
  • 5.3. PDE-5 Inhibitors
    • 5.3.1. Global Pulmonary Arterial Hypertension Market, by PDE-5 Inhibitors, by Region, 2019-2032 (USD Billion)
  • 5.4. Prostacyclin and Prostacyclin Analogs
    • 5.4.1. Global Pulmonary Arterial Hypertension Market, by Prostacyclin and Prostacyclin Analogs, by Region, 2019-2032 (USD Billion)
  • 5.5. SGC Stimulators
    • 5.5.1. Global Pulmonary Arterial Hypertension Market, by SGC Stimulators, by Region, 2019-2032 (USD Billion)
  • 5.6. Endothelin Receptor Antagonists (ERAs)
    • 5.6.1. Global Pulmonary Arterial Hypertension Market, by Endothelin Receptor Antagonists (ERAs), by Region, 2019-2032 (USD Billion)

6. Global Pulmonary Arterial Hypertension Market, by Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 6.3. Generics
    • 6.3.1. Global Pulmonary Arterial Hypertension Market, by Generics, by Region, 2019-2032 (USD Billion)
  • 6.4. Branded
    • 6.4.1. Global Pulmonary Arterial Hypertension Market, by Branded, by Region, 2019-2032 (USD Billion)

7. Global Pulmonary Arterial Hypertension Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
  • 7.3. Intravenous/ subcutaneous
    • 7.3.1. Global Pulmonary Arterial Hypertension Market, by Intravenous/ subcutaneous, By Region, 2019-2032 (USD Billion)
  • 7.4. Inhalational
    • 7.4.1. Global Pulmonary Arterial Hypertension Market, by Inhalational, By Region, 2019-2032 (USD Billion)
  • 7.5. Oral
    • 7.5.1. Global Pulmonary Arterial Hypertension Market, by Oral, By Region, 2019-2032 (USD Billion)

8. Global Pulmonary Arterial Hypertension Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Pulmonary Arterial Hypertension Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Pulmonary Arterial Hypertension Market - North America
    • 8.3.1. North America: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.3.2. North America: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.3.3. North America: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.3.4. Pulmonary Arterial Hypertension Market - U.S.
      • 8.3.4.1. U.S.: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.3.5. Pulmonary Arterial Hypertension Market - Canada
      • 8.3.5.1. Canada: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.4. Pulmonary Arterial Hypertension Market - Europe
    • 8.4.1. Europe: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.4. Pulmonary Arterial Hypertension Market - UK
      • 8.4.4.1. UK: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.5. Pulmonary Arterial Hypertension Market - France
      • 8.4.5.1. France: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.6. Pulmonary Arterial Hypertension Market - Germany
      • 8.4.6.1. Germany: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.7. Pulmonary Arterial Hypertension Market - Italy
      • 8.4.7.1. Italy: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.8. Pulmonary Arterial Hypertension Market - Spain
      • 8.4.8.1. Spain: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.9. Pulmonary Arterial Hypertension Market - Netherlands
      • 8.4.9.1. Netherlands: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.4.10. Pulmonary Arterial Hypertension Market - Russia
      • 8.4.10.1. Russia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.5. Pulmonary Arterial Hypertension Market - Asia Pacific
    • 8.5.1. Asia Pacific: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.4. Pulmonary Arterial Hypertension Market - China
      • 8.5.4.1. China: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.5. Pulmonary Arterial Hypertension Market - India
      • 8.5.5.1. India: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.6. Pulmonary Arterial Hypertension Market - Malaysia
      • 8.5.6.1. Malaysia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.7. Pulmonary Arterial Hypertension Market - Japan
      • 8.5.7.1. Japan: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.8. Pulmonary Arterial Hypertension Market - Indonesia
      • 8.5.8.1. Indonesia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.5.9. Pulmonary Arterial Hypertension Market - South Korea
      • 8.5.9.1. South Korea: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.6. Pulmonary Arterial Hypertension Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.6.4. Pulmonary Arterial Hypertension Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.6.5. Pulmonary Arterial Hypertension Market - UAE
      • 8.6.5.1. UAE: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.6.6. Pulmonary Arterial Hypertension Market - Israel
      • 8.6.6.1. Israel: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.6.7. Pulmonary Arterial Hypertension Market - South Africa
      • 8.6.7.1. South Africa: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
  • 8.7. Pulmonary Arterial Hypertension Market - Latin America
    • 8.7.1. Latin America: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.7.4. Pulmonary Arterial Hypertension Market - Mexico
      • 8.7.4.1. Mexico: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.7.5. Pulmonary Arterial Hypertension Market - Brazil
      • 8.7.5.1. Brazil: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)
    • 8.7.6. Pulmonary Arterial Hypertension Market - Argentina
      • 8.7.6.1. Argentina: Pulmonary Arterial Hypertension Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Pulmonary Arterial Hypertension Market, by Route of Administration, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Pulmonary Arterial Hypertension Market, by Type, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Bayer
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Gilead Sciences, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. GlaxoSmithKline
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Johnson & Johnson
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Lupin Pharmaceuticals, Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Sandoz Inc. (Novartis)
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Sun Pharmaceutical Industries, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Teva Pharmaceutical Industries Ltd.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. United Therapeutics Corporation
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Viatris Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development